Treatment Information

Back

Prostate Cancer treatment details. Hormone.

Massachusetts General Hospital Cancer Center, Boston, MA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:5City/State/Province:Boston, MA
Treatments:HormoneHospital:Massachusetts General Hospital Cancer Center
Drugs:Journal:Link
Date:Jan 2014

Description:

Patients:
This phase 3 study involved previously treated, metastatic castration-resistant prostate cancer patients who were divided into two separate treatment groups. Group A consisted of 584 patients with a median age of 69 years. Group B had 289 patients with a median age of 68 years.

Treatment:
Patients in group A were treated with the biologic therapy called sunitinib (a small-molecule receptor tyrosine kinase inhibitor) and the steroid hormone prednisone.

Patients in group B were treated with prednisone alone.

Toxicities:
Treatment-related deaths due to infection, heart/respiratory failure, and unknown causes were reported for group A. Grade 4 pulmonary embolism and anemia were also reported, as was grade 3 fatigue, hand-foot skin reaction, and mucosal inflammation/stomatitis.

Treatment-related deaths due to infection, heart/respiratory failure, and unknown causes were reported for group B. Grade 4 pulmonary embolism and anemia were also reported.

Results:
The median overall survival rates for groups A and B were 13.1 and 11.8 months, respectively.

Support:
This study was supported by Pfizer Inc.

Correspondence: Dr. M. Dror Michaelson; email: [email protected]



Back